Key result
Post-transplant cyclophosphamide linked to early cardiac complications in allogeneic stem cell transplant patients.
Why the study?
Post-transplant cyclophosphamide is widely used to reduce graft-versus-host disease risk in allogeneic stem cell transplantation but has been associated with early cardiac complications.
Post-transplant cyclophosphamide is associated with early cardiac complications, highlighting the need for collaborative assessment and decision-making by RNs and APPs.
Post-transplant cyclophosphamide (PTCy) is a widely used therapy for reducing the risk of graft-versus-host disease in patients undergoing allogeneic stem cell transplantation. PTCy has been associated with early cardiac comp.
No takes yet. Share an insight, caveat, or question.
Tia T Wheatley (2026) studied this question. Post-transplant cyclophosphamide is associated with early cardiac complications in patients undergoing allogeneic stem cell transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: